Mapi Pharma Provides Enrollment Update in Phase III GA Depot Clinical Trial
Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel...
Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel...
Transaction Expands Gainwell’s Capabilities as an Analytics-Driven Healthcare Technology Provider Cotiviti to Subsequently Acquire Certain Business Lines, Expanding Health Plan...
– exoIL-12 has demonstrated tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo...
Versamune® T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune responses in a COVID-19 vaccine PDS Biotech Announces Mount Sinai Publication...
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CannAssist International Corp. (OTCQB: CNSC) ("CannAssist International" or the...
DAVIS, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Farmers in Uruguay will have a new solution to grow a more...
NEW YORK and SYDNEY, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”),...
WARSAW, Ind., Dec. 21, 2020 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively...
PRESS RELEASE December 21, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced the...
Company announcement, Helsinki, 21 December 2020 at 15.15 (EET) Nexstim Plc’s Financial Information in 2021 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim"...
- Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease...
– Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration...
MIAMI, Dec. 21, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Roger Medel, M.D....
Dravet syndrome is a rare, debilitating and difficult-to-treat lifelong epilepsy that begins in infancyEC approval is based on Phase 3...
Equillium Further Strengthens Management Team with Additional Executive HiresLA JOLLA, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq:...
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline...
OREM, Utah, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), is a provider of diverse products and...
Trial underway at City of Hope to evaluate safety and feasibility of administering therapy in patients with brain tumors such...
Company affirms plans to begin enrollment of patients with HR+ HER2- metastatic breast cancer and other tumors in U.S. Phase...
LAFAYETTE, La., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a...